PURPOSE: Anorectal dysfunction is common after pelvic radiotherapy. This study aims to explore the relationship of subjective and objective anorectal function with quality of life (QoL) and their relative impact in patients irradiated for prostate cancer. METHODS: Patients underwent anal manometry, rectal barostat measurement, and completed validated questionnaires, at least 1 year after prostate radiotherapy (range 1-7 years). QoL was measured by the Fecal Incontinence Quality of Life scale (FIQL) and the Expanded Prostate Cancer Index Composite Bowel domain (EPICB)-bother subscale. Severity of symptoms was rated by the EPICB function subscale. RESULTS: Anorectal function was evaluated in 85 men. Sixty-three percent suffered from one or more anorectal symptoms. Correlations of individual symptoms ranged from r = 0.23 to r = 0.53 with FIQL domains and from r = 0.36 to r = 0.73 with EPICB bother scores. They were strongest for fecal incontinence and urgency. Correlations of anal sphincter pressures, rectal capacity, and sensory thresholds ranged from r = 0.00 to r = 0.42 with FIQL domains and from r = 0.15 to r = 0.31 with EPICB bother scores. Anal resting pressure correlated most strongly. Standardized regression coefficients for QoL outcomes were largest for incontinence, urgency, and anal resting pressure. Regression models with subjective parameters explained a larger amount (range 26-92 %) of variation in QoL outcome than objective parameters (range 10-22 %). CONCLUSIONS: Fecal incontinence and rectal urgency are the symptoms with the largest influence on QoL. Impaired anal resting pressure is the objective function parameter with the largest influence. Therefore, sparing the structures responsible for an adequate fecal continence is important in radiotherapy planning.
PURPOSE:Anorectal dysfunction is common after pelvic radiotherapy. This study aims to explore the relationship of subjective and objective anorectal function with quality of life (QoL) and their relative impact in patients irradiated for prostate cancer. METHODS:Patients underwent anal manometry, rectal barostat measurement, and completed validated questionnaires, at least 1 year after prostate radiotherapy (range 1-7 years). QoL was measured by the Fecal Incontinence Quality of Life scale (FIQL) and the Expanded Prostate Cancer Index Composite Bowel domain (EPICB)-bother subscale. Severity of symptoms was rated by the EPICB function subscale. RESULTS: Anorectal function was evaluated in 85 men. Sixty-three percent suffered from one or more anorectal symptoms. Correlations of individual symptoms ranged from r = 0.23 to r = 0.53 with FIQL domains and from r = 0.36 to r = 0.73 with EPICB bother scores. They were strongest for fecal incontinence and urgency. Correlations of anal sphincter pressures, rectal capacity, and sensory thresholds ranged from r = 0.00 to r = 0.42 with FIQL domains and from r = 0.15 to r = 0.31 with EPICB bother scores. Anal resting pressure correlated most strongly. Standardized regression coefficients for QoL outcomes were largest for incontinence, urgency, and anal resting pressure. Regression models with subjective parameters explained a larger amount (range 26-92 %) of variation in QoL outcome than objective parameters (range 10-22 %). CONCLUSIONS: Fecal incontinence and rectal urgency are the symptoms with the largest influence on QoL. Impaired anal resting pressure is the objective function parameter with the largest influence. Therefore, sparing the structures responsible for an adequate fecal continence is important in radiotherapy planning.
Authors: T H Rockwood; J M Church; J W Fleshman; R L Kane; C Mavrantonis; A G Thorson; S D Wexner; D Bliss; A C Lowry Journal: Dis Colon Rectum Date: 2000-01 Impact factor: 4.585
Authors: Robert Jan Smeenk; Bin S Teh; E Brian Butler; Emile N J Th van Lin; Johannes H A M Kaanders Journal: Radiother Oncol Date: 2010-05-05 Impact factor: 6.280
Authors: Abrahim Al-Mamgani; Wim L J van Putten; Wilma D Heemsbergen; Geert J L H van Leenders; Annerie Slot; Michel F H Dielwart; Luca Incrocci; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-19 Impact factor: 7.038
Authors: Mark K Buyyounouski; Eric M Horwitz; Robert A Price; Alexandra L Hanlon; Robert G Uzzo; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-01 Impact factor: 7.038
Authors: Eric E K Yeoh; Richard H Holloway; Robert J Fraser; Rochelle J Botten; Addolorata C Di Matteo; James W E Moore; Mark N Schoeman; F Dylan L Bartholomeusz Journal: Am J Gastroenterol Date: 2004-02 Impact factor: 10.864
Authors: Bradford S Hoppe; Jeff M Michalski; Nancy P Mendenhall; Christopher G Morris; Randal H Henderson; Romaine C Nichols; William M Mendenhall; Christopher R Williams; Meredith M Regan; Jonathan J Chipman; Catrina M Crociani; Howard M Sandler; Martin G Sanda; Daniel A Hamstra Journal: Cancer Date: 2013-12-30 Impact factor: 6.860
Authors: Maria Thor; Caroline E Olsson; Jung Hun Oh; Stine E Petersen; David Alsadius; Lise Bentzen; Niclas Pettersson; Ludvig P Muren; Ann-Charlotte Waldenström; Morten Høyer; Gunnar Steineck; Joseph O Deasy Journal: Acta Oncol Date: 2015-09-04 Impact factor: 4.089
Authors: Palak Kundu; Eric Y Lin; Stephanie M Yoon; Neil R Parikh; Dan Ruan; Amar U Kishan; Alan Lee; Michael L Steinberg; Albert J Chang Journal: Front Oncol Date: 2022-03-08 Impact factor: 6.244
Authors: Paul Sargos; Mame Daro Faye; Manon Bacci; Stéphane Supiot; Igor Latorzeff; David Azria; Tamim M Niazi; Te Vuong; Véronique Vendrely; Renaud de Crevoisier Journal: Front Oncol Date: 2021-06-16 Impact factor: 6.244
Authors: Ben G L Vanneste; Evert J Van Limbergen; Kees van de Beek; Emile van Lin; Ludy Lutgens; Philippe Lambin Journal: Tech Innov Patient Support Radiat Oncol Date: 2018-03-20